Literature DB >> 7994291

Motor Speech Treatment Hierarchy: a systems approach.

D A Hayden1, P A Square.   

Abstract

The Motor Speech Treatment Hierarchy used to guide PROMPT intervention represents a theoretical framework for the application of all bottom-up motor speech treatments. In addition, the hierarchy can be used prior to motor speech treatment to evaluate what aspects of the child's neuromotor system are intact and which elements are operating ineffectively or partially. When consideration is given to the development of the speech motor system and the interaction among the various valves and/or articulators, it becomes apparent that treatment must focus on the integration of all these aspects in order to be successful. The goal of intervention must be the voluntary control of all speech actions. But voluntary control of all speech actions is not possible for all children, and the clinician must realize that compensatory actions, although beneficial in the short term, will limit more complex interactions later. It is for these reasons that more attention should be given to mastery of control at the lower stages of the hierarchy. The clinician should not assume that all actions are intact based upon the perceived quality of speech. For the child with "pure" DAS, intervention usually begins at stage V or VI, whereas for children with developmental dysarthria, intervention begins at lower levels of the hierarchy. The responsibility, as always, lies with the clinician to determine the most appropriate level at which intervention should begin and the steps needed to achieve the best speech production. The clinician's knowledge provides the foundation for changing deviant motor speech patterns and for providing for our clients voluntary control of motor speech function. It has been the aim of this article to provide for clinicians a framework for treatment that will enhance their clinical effectiveness.

Entities:  

Mesh:

Year:  1994        PMID: 7994291

Source DB:  PubMed          Journal:  Clin Commun Disord        ISSN: 1054-8505


  7 in total

1.  Motor-based intervention protocols in treatment of childhood apraxia of speech (CAS).

Authors:  Edwin Maas; Christina Gildersleeve-Neumann; Kathy J Jakielski; Ruth Stoeckel
Journal:  Curr Dev Disord Rep       Date:  2014-09

2.  Changes in voice onset time and motor speech skills in children following motor speech therapy: Evidence from /pa/ productions.

Authors:  Vickie Y Yu; Darren S Kadis; Anna Oh; Debra Goshulak; Aravind Namasivayam; Margit Pukonen; Robert Kroll; Luc F De Nil; Elizabeth W Pang
Journal:  Clin Linguist Phon       Date:  2014-01-21       Impact factor: 1.346

3.  The sequential development of jaw and lip control for speech.

Authors:  Jordan R Green; Christopher A Moore; Kevin J Reilly
Journal:  J Speech Lang Hear Res       Date:  2002-02       Impact factor: 2.297

4.  Liuzijue qigong versus traditional breathing training for patients with post-stroke dysarthria complicated by abnormal respiratory control: Results of a single-center randomized controlled trial.

Authors:  Jie Wang; Gaiyan Li; Shanshan Ding; Long Yu; Yan Wang; Lei Qiao; Qilin Wu; Weidong Ni; Hang Fan; Qianyun Zheng; Ying Zhang; Hongli Li
Journal:  Clin Rehabil       Date:  2021-02-01       Impact factor: 3.477

5.  Assessment and management of the communication difficulties of children with cerebral palsy: a UK survey of SLT practice.

Authors:  Rose Mary Watson; Lindsay Pennington
Journal:  Int J Lang Commun Disord       Date:  2015-02-04       Impact factor: 3.020

6.  Motor development and motor resonance difficulties in autism: relevance to early intervention for language and communication skills.

Authors:  Joseph P McCleery; Natasha A Elliott; Dimitrios S Sampanis; Chrysi A Stefanidou
Journal:  Front Integr Neurosci       Date:  2013-04-24

Review 7.  Speech therapy for children with dysarthria acquired before three years of age.

Authors:  Lindsay Pennington; Naomi K Parker; Helen Kelly; Nick Miller
Journal:  Cochrane Database Syst Rev       Date:  2016-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.